疗效和安全性的Daprodustat在慢性肾脏疾病患者贫血治疗:系统回顾和荟萃分析。

文章的细节

引用
复制到剪贴板

太阳王郑Q, Y,杨H, L,傅X,魏R,刘YN,刘WJ

疗效和安全性的Daprodustat在慢性肾脏疾病患者贫血治疗:系统回顾和荟萃分析。

杂志。2021年1月12日,11:573645。doi: 10.3389 / fphar.2020.573645。eCollection 2020。

PubMed ID
33597868 (在PubMed
]
文摘

目的:Daprodustat是一种新型的口服剂在治疗贫血的慢性肾脏疾病(CKD),和几个临床试验进行比较Daprodustat重组人红细胞生成素(rhEPO)或安慰剂。我们的系统综述旨在调查daprodustat贫血治疗的有效性和安全性在dialysis-dependent (DD)和non-dialysis-dependent (NDD)患者。方法:检索了六个数据库,随机对照试验(相关的)报告dap必威国际approdustat与rhEPO或安慰剂在CKD贫血患者。结果指标都集中在血红蛋白(Hb)、铁蛋白、转铁蛋白饱和度(TSAT)、总铁扎能力(TIBC)、血管内皮生长因子(VEGF)和严重不良事件(节约)。结果:8个合格研究1516名参与者被包括在内。NDD和DD病人,Hb水平变化的基线daprodustat组显著高于安慰剂(平均差(MD) = 1.73(95%可信区间(CI), 0.34 - 3.12), p = 0.01;MD = 1.88 (95% CI, 0.68 - 3.09), p = 0.002;分别),没有明显区别daprodustat和rhEPO集团(MD = 0.05, (95% CI, -0.49 - 0.59), p = 0.86;MD = 0.12 (95% CI, -0.28 - 0.52), p = 0.55;分别)。 The indexes of iron metabolism were improved significantly in the daprodustat group compared to placebo- or rhEPO-treated patients, while there was no similar change in terms of TSAT for DD patients. Furthermore, no trend of increasing plasma VEGF was observed in daprodustat-treated subjects. As for safety, there was no significant difference in the incidence of SAEs between daprodustat and placebo treatment, while the incidence of SAEs in the daprodustat group was significantly lower than that in the rhEPO group. Conclusion: Daprodustat was efficacious and well tolerated for anemia in both NDD and DD patients in the short term based on current RCTs. And daprodustat may become an effective alternative for treatment of anemia with CKD. Since the application of daprodustat is still under exploration, future researches should consider the limitations of our study to evaluate the value of daprodustat.

DrugBank数据引用了这篇文章

药物
药物靶点
药物 目标 类 生物 药理作用 行动
Daprodustat Egl九同族体1 蛋白质 人类
是的
抑制剂
 细节
Daprodustat Egl九同族体2 蛋白质 人类
是的
抑制剂
 细节
Daprodustat Egl九同族体3 蛋白质 人类
是的
抑制剂
 细节